September 29, 2014Open Access

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations. (Funded by GlaxoSmithKline; Clinical Trials.gov number, NCT01584648.).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Long et al. (Mon,) studied this question.

synapsesocial.com/papers/699ec393713733805dde645a https://doi.org/https://doi.org/10.1056/nejmoa1406037

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations2012 · 2,798 citations
2BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact2014 · 542 citations
3Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma2014 · 42 citations
4Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma2012 · 2,141 citations
5Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).2011 · 122 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo